INT84211

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 1999
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 1.40
Pain Relevance 3.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
spinal 1
Cnrip1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cannabinoid 28 100.00 Very High Very High Very High
antagonist 9 100.00 Very High Very High Very High
Opioid 4 100.00 Very High Very High Very High
Serotonin 2 100.00 Very High Very High Very High
narcan 2 100.00 Very High Very High Very High
agonist 12 99.36 Very High Very High Very High
analgesia 11 99.02 Very High Very High Very High
Endocannabinoid 9 99.00 Very High Very High Very High
intrathecal 1 96.92 Very High Very High Very High
Gabapentin 1 94.12 High High
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 8 99.48 Very High Very High Very High
Heart Rate Under Development 5 91.80 High High
Gastric Motility Disorder 1 88.84 High High
Urological Neuroanatomy 3 87.44 High High
Shock 2 80.88 Quite High
Stress 2 75.00 Quite High
Cv Unclassified Under Development 1 72.52 Quite High
Recurrence 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is concluded that the discriminative stimulus effects of BAY 59-3074 are specifically mediated by cannabinoid CB1 receptor activation.
Positive_regulation (activation) of cannabinoid CB1 receptor associated with cannabinoid
1) Confidence 0.69 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15556145 Disease Relevance 0 Pain Relevance 0.63
This effect was mediated by stimulation of the cannabinoid CB1 receptor and required the activation of the endogenous opioid system.
Positive_regulation (stimulation) of cannabinoid CB1 receptor
2) Confidence 0.62 Published 2002 Journal Psychopharmacology (Berl.) Section Body Doc Link 11862347 Disease Relevance 0 Pain Relevance 0
These results suggest that cannabinoid agonists delay gastric emptying through activation of cannabinoid CB1 receptors, while the endogenous cannabinoid system does not seem to modulate gastric motility.
Positive_regulation (activation) of cannabinoid CB1 associated with cannabinoid and agonist
3) Confidence 0.57 Published 1999 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 10494894 Disease Relevance 0.09 Pain Relevance 0.69
CONCLUSIONS: The results show that the reinforcing and motivational effects of heroin and heroin-paired stimuli are mediated, at least in part, by activation of cannabinoid CB1 receptors.
Positive_regulation (activation) of cannabinoid CB1
4) Confidence 0.57 Published 2003 Journal Psychopharmacology (Berl.) Section Body Doc Link 12669182 Disease Relevance 0 Pain Relevance 0
Whereas the mechanism underlying the brief vasopressor effect (phase II) is unknown, the prolonged hypotension (phase III) results from stimulation of the cannabinoid CB1 receptor.
Positive_regulation (stimulation) of cannabinoid CB1 receptor associated with pressure volume 2 under development and cannabinoid
5) Confidence 0.53 Published 2001 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 11770012 Disease Relevance 0.83 Pain Relevance 0.51
The effect of the most effective dose (10 ng/rat) was prevented by pre-treatment with the CB1 cannabinoid (SR 141716A) [N-piperidino-5-(4-chlorophenyl) 1-(2, 4-dichloro-phenyl)-4-methyl pyrazole-3-carboxamide hydrochloride] (0.5 mg kg(-1)), the opioid (naloxone) (2 mg kg(-1)), and the serotonin 5-HT3, tropisetron [endo-8-methyl-8-azabicyclo [3.2.1] oct-3-olindol-3-yl-carboxylate hydrochloride] (1 mg kg(-1)), receptor antagonists, which did not induce place conditioning on their own.
Positive_regulation (induce) of CB1 cannabinoid associated with antagonist, cannabinoid, narcan, serotonin and opioid
6) Confidence 0.50 Published 2005 Journal Pharmacol. Res. Section Abstract Doc Link 15629265 Disease Relevance 0 Pain Relevance 0.42
Intrathecal administration of the competitive CB1 antagonist SR141716A (rimonabant) failed to suppress nonopioid SIA, suggesting that supraspinal rather than spinal CB1 receptor activation plays a pivotal role in endocannabinoid-mediated SIA.
Positive_regulation (activation) of CB1 receptor in spinal associated with endocannabinoid, antagonist, analgesia and intrathecal
7) Confidence 0.19 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16316669 Disease Relevance 0.48 Pain Relevance 1.57

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox